Alergia a la proteína de leche de vaca en la infancia: microbiota, hidrolizados y tolerancia

Trabajo presentado al XIII Workshop Sociedad Española de Microbiota, Probióticos y Prebióticos, celebrado en Valencia (España), del 7 la 9 de junio de 2022.Introducción La alergia a proteínas de leche de vaca (APLV) es la alergia alimentaria más frecuente en la infancia, habiéndose descrito posibles relaciones con la microbiota intestinal y con el tipo de alimentación. El objetivo de este trabajo es profundizar en el estudio de la microbiota intestinal en menores de un año con APLV y su relación con la adquisición de tolerancia y dieta, comparando muestras al diagnóstico y a los 6 meses de seguimiento con dieta de exclusión láctea. Metodología Se reclutaron 22 pacientes diagnosticados con APLV (14 mediados por IgE y 8 no mediados) y un grupo control de 25 niños sanos. Se recogieron muestras de heces y se realizó un análisis metataxonómico del ADNr 16S y de las regiones ITS de bifidobacterias por secuenciación. Se evaluaron las características clínico-epidemiológicas de los pacientes y se realizó un seguimiento a los 6 meses para evaluar tolerancia y el uso de distintas fórmulas terapéuticas de sustitución alimentaria. Resultados Se detectó un mayor porcentaje de secuencias pertenecientes al filo Actinobacteria (¿60%) en controles frente a casos (¿30%) al diagnóstico. Además, el patrón de abundancias relativas de bifidobacterias fue diferente entre controles y pacientes no mediados por IgE, con una menor proporción de B. longum en estos últimos. Tras la dieta de exclusión, sólo 3 de los pacientes, que estaban tomando distintos tipos de fórmulas terapéuticas, adquirió tolerancia, de los cuales 2 eran casos no mediados por IgE. Conclusiones En los pacientes APLV no IgE mediada se observaron perfiles microbianos distintos de los lactantes sanos, encontrándose a su vez en este grupo una mayor tolerancia al cabo de 6 meses. En tratamiento y seguimiento de la APLV la determinación de la microbiota intestinal puede ser clave para establecer posibles vínculos con la adquisición de tolerancia y el tipo de hidrolizado

Estudio para la mejora de la calidad del vino albariño

Premio de Investigación, Real Academia Galega de Ciencias, convocatoria 2009.[EN]Twenty-two clones from Albariño variety (Vitis vinifera L.), from an initial collection of 115 clones, were selected on the basis of their ampelographic, molecular and sanitary characteristics. These selected clones were studied from the agronomic and oenological point of view, and were also quantified for their levels of susceptibility to Powdery Mildew, Oidium and Botrytis. An ecotypic yeast was selected, its use has been patented and it is being exploited. Musts obtained from the previously selected Albariño clones were fermented with this yeast, essentially by increasing the content in volatile substances of interest (terpens: linalool and geraniol; norisoprenoids: α-ionone and β- damascenone), leading to wines with improved fermentative dynamic and sensorial attributes.[ES]En base a características ampelográficas, moleculares y sanitarias, se seleccionaron 22 clones de la variedad Albariño (Vitis vinifera L.), partiendo de 115 iniciales. Sobre los clones seleccionados se ha llevado a cabo un estudio agronómico y enológico, así como la cuantificación de los niveles de susceptibilidad a Mildiu, Oídio y Botrytis. Se ha seleccionado una levadura ecotípica, cuyo uso ha sido patentado y se encuentra en explotación. Con ella se fermentaron los mostos obtenidos a partir de los clones de Albariño previamente seleccionados, dando lugar a vinos con una dinámica fermentativa xPremio de Investigación, Real Academia Galega de Ciencias, convocatoria 2009 y unos atributos sensoriales mejorados, fundamentalmente en base al aumento del contenido en sustancias volátiles de interés (terpenos: linalool y geraniol; norisoprenoides: α-ionona y β- damascenona).La actividad realizada ha sido financiada, además de por la Bodega Terras Gauda S.A., por la Xunta de Galicia (PGIDIT04TAL035E), y por el propio CSIC (PIE 2004 7 0E 214).Peer reviewe

Self-perceived level of competitiveness, tension and dependency and depression risk in the SUN cohort

Background: Emerging evidence suggests a possible etiologic role of certain personality traits (not necessary dysfunctional) in the risk of depression, but the longitudinal long-term available evidence is currently scarce. We longitudinally assessed whether 3 common personality traits (competitiveness, tension and dependency) were associated with the risk of depression after a maximum follow-up of 15 years. Methods: We assessed 15,604 university graduates free of depression at baseline through a self-administered questionnaire including personality traits. Simple, Likert-type, questions with 11 possible answers ranging from 0 to 10 were used at baseline to assess the 3 personality traits. We compared participants with high scores (7–10) versus those with low scores (0–4). New medical diagnoses of depression during follow-up were used as the outcome. Results: During a median follow-up of 10.1 y, we prospectively identified 902 new medical diagnoses of depression. The multivariable-adjusted hazard ratios (95% confidence intervals) for depression were 1.85 (1.52–2.24) for participants with higher baseline tension (7–10 versus 0 to 4), P-trend < 0.001; and 1.23 (1.06–1.44) for high versus low baseline dependence levels, P-trend = 0.004. Higher levels of competitiveness were marginally associated with lower risk of depression, with hazard ratio = 0.78 (0.61–1.01), P-trend = 0.105. Conclusion: A simple scoring system of personality traits shows an independent association with the future occurrence of depression. This finding underscores, with now prospective evidence, the importance of personality traits in the aetiology of depression and can provide a clinically useful tool for gathering valid information about depression-related personality traits

Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis

ObjectiveTo investigate the effect of menarche, pregnancies, and breastfeeding on the risk of developing multiple sclerosis (MS) and disability accrual using a multivariate approach based on a large prospective cohort of patients with clinically isolated syndrome (CIS).MethodsA cross-sectional survey of the reproductive information of female participants in a CIS cohort was performed. We examined the relationship of age at menarche with the risk of clinically definite MS (CDMS), McDonald 2010 MS, and Expanded Disability Status Scale (EDSS) 3.0 and 6.0. The effect of pregnancy (before and after CIS) and breastfeeding in the risk of CDMS, McDonald 2010 MS, and EDSS 3.0 was also examined. Univariate and multivariate analyses were performed and findings were confirmed using sensitivity analyses and a propensity score model.ResultsThe data of 501 female participants were collected. Age at menarche did not correlate with age at CIS and was not associated with the risk of CDMS or EDSS 3.0 or 6.0. Pregnancy before CIS was protective for CDMS in the univariate analysis, but the effect was lost in the multivariate model and did not modify the risk of EDSS 3.0. Pregnancy after CIS was protective for both outcomes in univariate and multivariate analyses when pregnancy was considered a baseline variable, but the protective effect disappeared when analyzed as a time-dependent event. Breastfeeding did not modify the risk for the 3 outcomes.ConclusionsThese results demonstrate that menarche, pregnancies, and breastfeeding did not substantially modify the risk of CDMS or disability accrual using a multivariable and time-dependent approach

Avenços tecnològics aplicats a la inspecció

Control oficial; Inspecció; Eines; ProcessosControl oficial; Inspección; Herramientas; ProcesosOfficial control; Inspection; Tools; ProcessesAquest és un treball fet per una comunitat de pràctica (CoP) que es va constituir l’any 2015 i ha treballat dues temporades consecutives. L'objectiu ha estat elaborar propostes encaminades a augmentar la qualitat i l’eficiència del procés d’inspecció i control oficial, millorar la comunicació i la informació que es dona a la persona inspeccionada, i incrementar el grau de satisfacció de totes les parts implicades en el procés d’inspecció. Per tal d’aconseguir-ho, ens vam marcar dues línies de treball recollides en aquest treball: 1-Detectar les necessitats de les diferents parts implicades en el procés d’inspecció. 2-Avaluar les eines que s’utilitzen actualment a l’Agència de Salut Pública de Catalunya (ASPCAT), en altres departaments i administracions i en l’empresa privada, per tal de valorar les oportunitats de millora.Éste es un trabajo realizado por una comunidad de práctica (CoP) que se constituyó en 2015 y ha trabajado dos temporadas consecutivas. El objetivo ha sido elaborar propuestas encaminadas a aumentar la calidad y eficiencia del proceso de inspección y control oficial, mejorar la comunicación y la información que se da a la persona inspeccionada, e incrementar el grado de satisfacción de todas las partes implicadas en el proceso de inspección. Para conseguirlo, nos marcamos dos líneas de trabajo recogidas en este trabajo: 1-Detectar las necesidades de las diferentes partes implicadas en el proceso de inspección. 2-Evaluar las herramientas que se utilizan actualmente en la Agencia de Salud Pública de Cataluña (ASPCAT), en otros departamentos y administraciones y en la empresa privada, para valorar las oportunidades de mejora.This is work carried out by a community of practice (CoP) that was established in 2015 and has worked for two consecutive seasons. The objective has been to develop proposals aimed at increasing the quality and efficiency of the official inspection and control process, improving communication and information given to the inspected person, and increasing the degree of satisfaction of all parties involved in the inspection process. inspection. To achieve this, we set out two lines of work included in this work: 1-Detect the needs of the different parties involved in the inspection process. 2-Evaluate the tools currently used in the Public Health Agency of Catalonia (ASPCAT), in other departments and administrations and in private companies, to assess opportunities for improvement

Búsqueda de marcadores intestinales asociados a alergia a la proteína de leche de vaca

Resumen trabajo presentado en el XII Workshop Sociedad Española de Microbiota, Probióticos y Prebióticos (SEMiPyP) y I Congreso Sociedad Iberoamericana de Microbiota, Probióticos y Prebióticos (SIAMPYP), celebrado de forma virtual del 15 al 18 de septiembre de 2021.Introducción. De las reacciones de hipersensibilidad causadas por alimentos, la alergia a la proteína de la leche de vaca (APLV) es la más común en los lactantes. En la mayoría de casos se trata de una alergia mediada por IgE, si bien las formas no mediadas son las más desconocidas y difíciles de diagnosticar, con una afectación retardada y fundamentalmente digestiva. Dentro de estas destaca por su gravedad el síndrome de enterocolitis inducida por proteínas de leche de vaca (FPIES). Objetivo. El objetivo de este estudio es buscar biomarcadores microbianos e inflamatorios en heces asociados con distintas formas de presentación de APLV que pudieran facilitar el diagnóstico de estas patologías en la infancia. Metodología. Se parte de un grupo de pacientes = 1 año con distintas formas de presentación de APLV reclutados a lo largo de un año en tres Hospitales de Asturias. Con fines comparativos, se recluta en centros de atención primaria un grupo control de lactantes sanos sin ninguna enfermedad digestiva ni alérgica. A partir de las heces de los niños se realiza el análisis de parámetros inflamatorios, así como de la composición microbiana y de sus metabolitos. Resultados. Se detectaron distintos perfiles entre el grupo control y los pacientes en función del tipo de hipersensibilidad. Destaca la disminución de la excreción fecal de ácidos grasos de cadena corta (AGCC) en aquellos niños con formas no mediadas por IgE respecto al grupo de niños sanos y a los pacientes con APLV mediada por IgE. Conclusiones. Las poblaciones microbianas que se desarrollan en el intestino del lactante y la producción de metabolitos bacterianos específicos pueden ser claves en la interacción con el sistema inmunitario del lactante en este tipo de alergias. El análisis de muestras de heces podría ayudar al diagnóstico, sobre todo en los casos no mediados por IgE

Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia

Altres ajuts: this project was supported by the Asociación Española Contra el Cáncer (project ref: GC16173697BIGA), [...], and Obra Social "La Caixa"

The long-term outcomes of CIS patients in the Barcelona inception cohort : Looking back to recognize aggressive MS

Altres ajuts: This study has been funded by European Regional Development Fund and co-funded by Instituto Carlos III. It has also received support by a grant from Genzyme foundation (GENZYME-2015-01) granted to M.T. and from the 'Red Española de Esclerosis Múltiple (REEM)', which is sponsored by FIS, the Instituto de Salud Carlos III, the Ministry of Economy and Competitiveness in Spain, and the 'Ajuts per donar Suport als Grups de Recerca de Catalunya', which is sponsored by the 'Agència de Gestió d'Ajuts Universitaris i de Recerca' (AGAUR) of the Generalitat de Catalunya in Spain.To explore the long-term outcomes of patients with clinically isolated syndromes from the Barcelona cohort. We selected patients with a follow-up longer than 10 years to (1) estimate the risks of multiple sclerosis (MS) and disability accumulation according to the baseline number of T2 lesions and to compare treated versus untreated patients and early versus delayed treatment, and (2) to study baseline features of patients with aggressive MS (Expanded Disability Status Scale (EDSS) ⩾6.0 at 10 years). In all, 401 patients were included (mean follow-up of 14.4 (standard deviation of 2.9) years). A higher number of T2 lesions was associated with an earlier MS diagnosis and an earlier risk of irreversible disability. Early treatment was associated with a decreased risk of EDSS of 3.0: adjusted hazard ratio = 0.4, 95% confidence interval = (0.2, 0.7). Patients with aggressive MS differed in their baseline brain magnetic resonance images: The median (interquartile range) number of T2 lesions and contrast-enhancing lesions (CEL) was 71 (28-95) versus 7 (1-19) and 3 (1-24) versus 0 (0-1), respectively. The cut-offs that better classified patients with aggressive MS were 20 for T2 lesions and 2 for CEL. Although MS natural history is changing, a high lesion load at onset is helpful to identify patients at risk of presenting an aggressive MS

Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia

© The Author(s).Recurrent deletions of the CDKN2A/ARF/CDKN2B genes encoded at chromosome 9p21 have been described in both pediatric and adult acute lymphoblastic leukemia (ALL), but their prognostic value remains controversial, with limited data on adult T-ALL. Here, we investigated the presence of homozygous and heterozygous deletions of the CDKN2A/ARF and CDKN2B genes in 64 adult T-ALL patients enrolled in two consecutive trials from the Spanish PETHEMA group. Alterations in CDKN2A/ARF/CDKN2B were detected in 35/64 patients (55%). Most of them consisted of 9p21 losses involving homozygous deletions of the CDKNA/ARF gene (26/64), as confirmed by single nucleotide polymorphism (SNP) arrays and interphase fluorescence in situ hybridization (iFISH). Deletions involving the CDKN2A/ARF/CDKN2B locus correlated with a higher frequency of cortical T cell phenotype and a better clearance of minimal residual disease (MRD) after induction therapy. Moreover, the combination of an altered copy-number-value (CNV) involving the CDKN2A/ARF/CDKN2B gene locus and undetectable MRD (≤ 0.01%) values allowed the identification of a subset of T-ALL with better overall survival in the absence of hematopoietic stem cell transplantation.This project was supported by the Asociación Española Contra el Cáncer, AECC (project ref.: GC16173697BIGA), by CERCA Program/Generalitat de Catalunya, the Catalan Government: 2014-SGR225 (GRE), Obra Social “La Caixa” and by Celgene Spain. E. Genescà is the recipient of agrant from the Spanish Health Ministry (ISCIII, CA12/00468) and an unrestricted grant from Gilead.A. Gonzalez-Perez is supported by a Ramon y Cajal fellowship (RYC-2013-14554) of the Educational Ministry (Madrid, Spain). This work was also partially supported by FEDER funds from the ISCIII (PT13/0010/0026, CIBERONC (CB16/12/00284 and CB16/12/00400), Madrid, Spain)

A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients

Complete remission (CR) after induction therapy is the first treatment goal in acute myeloid leukemia (AML) patients and has prognostic impact. Our purpose is to determine the correlation between the observed CR/CRi rate after idarubicin (IDA) and cytarabine (CYT) 3 + 7 induction and the leukemic chemosensitivity measured by an ex vivo test of drug activity. Bone marrow samples from adult patients with newly diagnosed AML were included in this study. Whole bone marrow samples were incubated for 48 h in well plates containing IDA, CYT, or their combination. Pharmacological response parameters were estimated using population pharmacodynamic models. Patients attaining a CR/CRi with up to two induction cycles of 3 + 7 were classified as responders and the remaining as resistant. A total of 123 patients fulfilled the inclusion criteria and were evaluable for correlation analyses. The strongest clinical predictors were the area under the curve of the concentration response curves of CYT and IDA. The overall accuracy achieved using MaxSpSe criteria to define positivity was 81%, predicting better responder (93%) than non-responder patients (60%). The ex vivo test provides better yet similar information than cytogenetics, but can be provided before treatment representing a valuable in-time addition. After validation in an external cohort, this novel ex vivo test could be useful to select AML patients for 3 + 7 regimen vs. alternative schedules